Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 282

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 282
---
 The April 2025 Loans shall bear interest at 8% per annum until maturity and the Company agreed 
 to pay the lenders an additional risk premium equal to 50% of their respective loan amount.    |

The April 2025 Loan's maturity
date is the earlier of August 31, 2025, or the date of consummation of a Qualified IPO. Furthermore, upon the occurrence of a
Qualified IPO, the April 2025 Loan lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to two times
their respective loan amount in addition to the risk premium based on a price per share equal to 75% of the lowest price per share
of the Ordinary Shares during the first five trading days following the consummation of such IPO.

| E. | On                                                                                             
 July 1, 2025, the Company entered into amendments of the Bridge Loans, the January 2024 Loan,  
 the December 2024 Loan Agreement and the April 2025 Loan Agreements such that the lenders      
 party thereto shall be granted with a fixed number of warrants to purchase such number of      
 Ordinary Shares following the consummation of a Qualified IPO, in amounts of 140,000 warrants, 
 61,539 warrants, 55,224 warrants and 92,309 warrants, respectively.                            |

| F. | Regarding settlement              
 agreement with CSL, see Note 9.5. |

<div align='center'>F-30

1,000,000 Ordinary Shares

Regentis Biomaterials Ltd.</div>

| PRELIMINARY PROSPECTUS |

<div align='center'>ThinkEquity

, 2025</div>

Through and including ,
2025 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating
in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer’s obligation to
deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.

<div align='center'>PART II

INFORMATION NOT REQUIRED IN PROSPECTUS</div>

Item 6. Indemnification of Directors, Officers and Employees.

Under the Companies Law,
a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an
office holder in advance from liability to the company, in